LO JUNEL FE Drug Patent Profile

When do Lo Junel Fe patents expire, and when can generic versions of Lo Junel Fe launch?

Lo Junel Fe is a drug marketed by Teva Pharms Inc and is included in one NDA.

The generic ingredient in LO JUNEL FE is ethinyl estradiol; norethindrone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for LO JUNEL FE

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	LO JUNEL FE at DailyMed

US Patents and Regulatory Information for LO JUNEL FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Inc	LO JUNEL FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	219324-001	Jun 22, 2026	AB	RX	No	No

Junel Fe Market Dynamics and Financial Trajectory

Last updated: August 17, 2026

Junel Fe is a low-cost combined oral contraceptive containing norethindrone acetate and ethinyl estradiol, with ferrous fumarate tablets included in the package. Its commercial position is driven by generic substitution, pharmacy purchasing, payer formulary placement, and supply reliability rather than brand pricing or patent exclusivity. Standalone revenue is not publicly disclosed, and Junel Fe should be analyzed as a multi-manufacturer generic franchise rather than as a single-company asset.

What is Junel Fe and how is it positioned in the contraceptive market?

Junel Fe is marketed in multiple strengths, principally Junel Fe 1/20 and Junel Fe 1.5/30.

Product	Active hormonal ingredients	Estrogen dose	Iron component
Junel Fe 1/20	Norethindrone acetate and ethinyl estradiol	20 mcg ethinyl estradiol	Ferrous fumarate tablets
Junel Fe 1.5/30	Norethindrone acetate and ethinyl estradiol	30 mcg ethinyl estradiol	Ferrous fumarate tablets

The hormonal tablets are followed by ferrous fumarate tablets. The iron tablets do not provide contraceptive activity. The product is used for pregnancy prevention in patients who elect an oral combined hormonal contraceptive [1].

Junel Fe competes with:

• Other norethindrone acetate and ethinyl estradiol generics
• Microgestin Fe
• Blisovi Fe
• Larin Fe
• Hailey Fe
• Tarina Fe
• Minastrin 24 Fe and related branded or authorized-generic products
• Lo Loestrin Fe, a lower-dose branded product containing norethindrone acetate and ethinyl estradiol

The main commercial distinction is dose, packaging, prescriber familiarity, and payer status. Molecular differentiation is limited because the market contains several therapeutically substitutable products.

How does Junel Fe generate revenue?

Junel Fe revenue is volume-driven and usually divided among manufacturers, wholesalers, pharmacies, and payers. Public companies generally report oral contraceptives within broader generic pharmaceutical revenue categories rather than disclosing Junel Fe sales separately.

The principal revenue drivers are:

1. Prescription volume and refill persistence
2. Generic dispensing rates
3. Formulary placement
4. Average selling price
5. Contract awards with wholesalers and pharmacy chains
6. Manufacturing availability
7. State Medicaid and commercial payer reimbursement
8. Patient copayment and contraceptive coverage rules

The product has recurring demand because oral contraceptives are dispensed monthly or in extended-cycle quantities. That recurring volume is offset by low pricing and intense competition. Generic suppliers can gain prescriptions quickly when a competitor experiences a manufacturing interruption, but the advantage can reverse when supply normalizes.

A reasonable financial characterization is:

• High prescription repeatability
• Low unit pricing
• Low to moderate gross margin
• Limited pricing power
• High sensitivity to supply and procurement contracts
• Low standalone disclosure value for diversified manufacturers

Junel Fe is therefore more valuable as part of a broad generic women’s-health portfolio than as an individual high-margin product.

When did Junel Fe lose exclusivity?

Junel Fe does not have the exclusivity profile of a recently launched branded drug. The underlying norethindrone acetate and ethinyl estradiol combination has been commercially available for decades, and multiple generic versions are approved by the FDA.

The earlier branded Loestrin and related products generated the commercial opportunity that later supported generic alternatives. By the time Junel Fe and comparable products reached broad distribution, the relevant active-ingredient combination was exposed to generic competition. The market is now post-exclusivity and should not be valued on a future patent-expiration thesis.

Exclusivity category	Junel Fe position
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current protection identified
New-product exclusivity	Expired or not commercially relevant
Generic competition	Established
Biosimilar exclusivity	Not applicable

FDA approval of generic oral contraceptives is generally supported through abbreviated new drug applications, which rely on bioequivalence to a reference-listed drug rather than new clinical efficacy trials [2].

What is the Orange Book status of Junel Fe?

Junel Fe products are generally associated with abbreviated new drug applications and generic-equivalent competition. The FDA Orange Book identifies reference-listed drugs, therapeutic-equivalence information, and patent or exclusivity data where applicable [3].

The commercial implications are more important than the listing mechanics:

• Junel Fe is exposed to AB-rated generic competition.
• A manufacturer cannot generally rely on a product-specific patent moat.
• Substitution can occur at the pharmacy level where state law and payer rules permit.
• Contracting and availability have greater influence than patent enforcement.
• Orange Book patent litigation is not the principal market risk for Junel Fe.

The precise manufacturer and application number can vary by presentation and supply source. Pharmaceutical companies may market equivalent products under different labels, creating a fragmented competitive set.

What patents protect Junel Fe?

No current patent estate is generally recognized as the primary commercial barrier for standard Junel Fe tablets. The active ingredients and basic oral dosage form are mature technologies.

Potential historical or secondary patent categories include:

• Hormonal composition patents
• Dosing-regimen patents
• Packaging patents
• Formulation patents
• Manufacturing-process patents
• Drug-delivery patents
• Patents covering low-dose estrogen combinations

These categories have limited relevance to standard generic Junel Fe unless a particular manufacturer relies on a protected formulation or process. Generic versions typically avoid unexpired claims through formulation design, certification, or litigation strategy.

The strongest remaining intellectual-property risks would more likely concern a branded low-dose product such as Lo Loestrin Fe, an extended-cycle regimen, or a novel delivery system rather than conventional Junel Fe tablets.

What formulation patents protect Junel Fe?

The conventional Junel Fe formulation has limited differentiation. Its commercial design consists of hormone-containing tablets followed by ferrous fumarate tablets. The iron component is a packaging and regimen feature rather than a major technological barrier.

Potential formulation disputes could involve:

• Release characteristics of the active tablets
• Excipient composition
• Tablet coating
• Stability or moisture protection
• Blister-pack configuration
• Dosing sequence
• Substitution of ferrous fumarate with another inert or supplemental tablet

These features do not normally create a durable barrier comparable with injectable delivery systems, modified-release products, or biologic manufacturing platforms. A competitor can often develop a therapeutically equivalent product without copying a narrow formulation claim.

Which companies are challenging Junel Fe commercially?

Competition comes from both branded and generic manufacturers. The most relevant competitors are not necessarily patent challengers. They are suppliers competing for the same pharmacy and payer volume.

Generic competitors

Generic norethindrone acetate and ethinyl estradiol products include products sold under names such as:

• Microgestin Fe
• Blisovi Fe
• Larin Fe
• Hailey Fe
• Tarina Fe
• Other manufacturer-specific Junel Fe equivalents

The manufacturers and label holders can change as products are acquired, divested, relabeled, or transferred among generic companies.

Branded competitors

Lo Loestrin Fe is the most direct branded comparator because it uses the same broad hormonal class but a lower ethinyl estradiol dose and a different regimen. Its brand positioning depends on physician familiarity, patient preference, promotional activity, and insurance coverage.

Other combined oral contraceptives compete for the same treatment category but differ in progestin, estrogen dose, adverse-effect profile, and patient-specific prescribing considerations.

What is the FDA regulatory status of Junel Fe?

Junel Fe is an FDA-approved combined oral contraceptive category marketed through generic approvals and reference-product pathways. The regulatory risk is low relative to products requiring new clinical trials, but manufacturing compliance remains material.

Key regulatory risks include:

• FDA inspection findings
• Manufacturing-site changes
• Batch failures
• Labeling deficiencies
• Serialization and supply-chain controls
• Product recalls
• Shortages caused by active-ingredient or packaging constraints

Because the product is mature, regulatory value comes from maintaining approval and reliable supply. A manufacturer that loses approval, encounters a warning letter, or cannot fulfill pharmacy orders can lose market share rapidly.

How strong is the Junel Fe patent estate?

The Junel Fe patent estate is weak as a standalone investment thesis.

Patent-strength factor	Assessment
Composition-of-matter protection	Very weak or expired
Core formulation protection	Limited
Manufacturing protection	Possible but narrow
Method-of-use protection	Limited for conventional contraception
Orange Book litigation leverage	Low
Generic entry barrier	Low
Commercial durability	Dependent on supply and contracts

Method-of-use claims covering contraception are unlikely to provide meaningful exclusivity for a mature combination product. Any remaining claims would need to be evaluated product by product, but they are unlikely to prevent broad generic substitution.

Are there Paragraph IV challenges involving Junel Fe?

Paragraph IV litigation is not the central commercial issue for an established Junel Fe generic. Paragraph IV certifications are most consequential when a generic applicant seeks approval before listed patents expire and challenges patents covering a branded reference product.

For mature norethindrone acetate and ethinyl estradiol products:

• Generic entry has already occurred.
• Multiple suppliers reduce the value of a single challenge.
• Litigation risk is more relevant to newer branded comparators.
• A Paragraph IV event involving Lo Loestrin Fe or another branded product would not necessarily affect the availability of standard Junel Fe.

Any litigation assessment must distinguish the product label, strength, ANDA, and reference-listed drug. The same active ingredients can appear in products with different patent positions.

What generic entry risks exist for Junel Fe?

Generic entry risk is already realized rather than prospective. The main risk to an existing Junel Fe supplier is further share erosion.

The most likely commercial scenarios are:

Base case: stable low-price competition

Several manufacturers continue supplying the market. Prescription volume remains recurring, while net prices remain constrained. Revenue grows only through market expansion, product-line additions, or share gains.

Upside case: supply disruption at a competitor

A manufacturing interruption or shortage at another supplier allows available manufacturers to raise shipments and capture temporary pharmacy demand. The benefit may be meaningful for a small generic portfolio but usually fades as competitors return.

Downside case: price compression

Additional suppliers enter, payer contracts tighten, or wholesalers shift purchasing volume. Unit prices decline, reducing revenue even if prescription volume remains stable.

Severe downside case: manufacturing or compliance failure

A supplier loses production capacity or encounters a regulatory issue. Revenue can fall sharply because pharmacies substitute immediately when inventory is unavailable.

How does Junel Fe compare with Lo Loestrin Fe?

Attribute	Junel Fe	Lo Loestrin Fe
Commercial status	Generic-oriented	Branded
Typical estrogen dose	20 or 30 mcg, depending on strength	Ultra-low-dose regimen
Pricing power	Low	Higher before generic erosion
Patent relevance	Limited	More relevant
Promotion	Primarily trade and payer driven	Brand and prescriber driven
Revenue disclosure	Usually embedded in generic sales	May be disclosed within branded portfolio
Main risk	Price and supply competition	Patent, payer, and generic-entry risk

Lo Loestrin Fe may command a premium because of dose and branding, but it carries greater exposure to patent expiry, Paragraph IV challenges, and brand-to-generic conversion. Junel Fe has lower strategic upside but lower dependence on a single exclusivity event.

What licensing deals affect Junel Fe?

Junel Fe is not generally associated with a high-value licensing transaction or platform-level commercial partnership. Generic oral contraceptive products can change hands through:

• ANDA acquisitions
• Product divestitures
• Contract manufacturing agreements
• Label-license arrangements
• Portfolio purchases
• Wholesale supply contracts

These transactions often occur without standalone financial disclosure. Their value depends on approved applications, manufacturing capacity, inventory, and customer contracts rather than patent rights.

What is the expected financial trajectory for Junel Fe?

Junel Fe should be modeled as a mature generic with a flat-to-declining price curve and relatively stable underlying demand.

A product-level forecast should use:

• Prescription volume by strength
• Net price per prescription
• Manufacturer market share
• Payer mix
• Refill rate
• Supply interruption probability
• Wholesale and pharmacy deductions
• Manufacturing cost per pack

The likely trajectory is:

1. Stable demand supported by recurring contraception use.
2. Continued price pressure from interchangeable generics.
3. Occasional volume spikes when competitors face shortages.
4. Limited value from patent-driven price expansion.
5. Greater strategic value when bundled with other women’s-health products.

Standalone revenue should not be estimated from a branded-drug model. The appropriate framework is a high-volume, low-price generic model with sensitivity to supply events.

Key Takeaways

• Junel Fe is a mature generic oral contraceptive based on norethindrone acetate and ethinyl estradiol.
• Its commercial value is driven by prescription volume, payer access, and supply reliability.
• No meaningful current composition-of-matter or formulation moat is central to the product’s value.
• Generic entry is already established, so future risk is share erosion rather than first entry.
• Orange Book and Paragraph IV issues are more relevant to branded comparators such as Lo Loestrin Fe.
• Standalone Junel Fe revenue is generally not publicly disclosed.
• The expected financial path is stable demand with persistent pricing pressure.
• Manufacturing compliance and availability are more important than patent litigation for current suppliers.

FAQs About Junel Fe Market Economics

Is Junel Fe a branded drug or a generic?

Junel Fe is generally positioned as a generic oral contraceptive product, although labeling and distribution can differ by manufacturer.

Does Junel Fe have biosimilar competition?

No. Biosimilars apply to biologic products. Junel Fe is a synthetic small-molecule oral tablet and competes with generic equivalents.

Can a pharmacy substitute another product for Junel Fe?

Substitution depends on FDA therapeutic-equivalence ratings, state pharmacy law, prescriber instructions, payer rules, and product availability.

Is Junel Fe exposed to contraceptive-policy changes?

Yes. Coverage mandates, Medicaid reimbursement, reproductive-health policy, and changes in prescription access can affect utilization and payer mix.

What would increase Junel Fe’s commercial value?

The strongest near-term drivers would be supply shortages at competing manufacturers, increased market share, new payer contracts, reliable manufacturing, and acquisition of complementary women’s-health products.

References

1. U.S. Food and Drug Administration. (n.d.). Junel Fe prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2014). Abbreviated new drug application approvals. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.